Redhill Biopharma LTD
Tel Aviv-Yafo, Tel Aviv District
- UEI
- NKN1XZ8D6KG5
- CAGE
- 2967A
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- HaArba'a St 21, Tel Aviv-Yafo, Israel
- Website
- redhillbio.com
- Founded
- 2009
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Redhill biopharma LTD-opaganib as host-directed therapeutic for ebola virus disease | Office of the Assistant Secretary for Preparedness and Response | $733,382 |
About Redhill Biopharma LTD
Redhill Biopharma LIMITED is a for-profit, corporate entity registered in SAM.gov since July 2011, with a current registration valid through September 2025. Classified as a Subcontinent Asian (Asian-Indian) American owned business, the company appears to specialize in pharmaceutical research and development, with a particular focus on developing therapeutic interventions for complex medical conditions. The organization is a foreign-owned enterprise that provides specialized biotechnology and pharmaceutical research services to U.S. federal agencies, with a notable emphasis on developing innovative drug therapies for challenging medical challenges.
The most recent federal contract award demonstrates the company's sophisticated capabilities in medical research, specifically a $733,381.75 contract from the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR). This contract focuses on developing opaganib as a host-directed therapeutic for Ebola virus disease, highlighting Redhill Biopharma's expertise in advanced pharmaceutical research targeting critical infectious disease treatments. The contract, awarded on September 27, 2024, with a completion date of October 31, 2025, is a firm-fixed-price definitive contract that was not set aside for any special designation, indicating the company's ability to compete in open federal contracting environments.
While the provided information details only one specific federal contract, the award demonstrates Redhill Biopharma's capabilities in developing advanced pharmaceutical interventions for complex medical challenges. The contract with HHS suggests the company has significant research capabilities in developing therapeutic solutions for infectious diseases, with a particular focus on innovative drug development strategies. The company's registration in SAM.gov and its ability to secure federal contracts indicate a sophisticated understanding of federal procurement processes and the scientific expertise required to develop cutting-edge medical treatments. The contract's focus on Ebola virus disease research underscores the company's commitment to addressing critical global health challenges through advanced pharmaceutical research and development.
Quick answers
What is Redhill Biopharma LTD's UEI?
Redhill Biopharma LTD's Unique Entity ID (UEI) in SAM.gov is NKN1XZ8D6KG5.
What is Redhill Biopharma LTD's CAGE code?
Redhill Biopharma LTD's CAGE code is 2967A.
What is Redhill Biopharma LTD's primary NAICS code?
Redhill Biopharma LTD's primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Redhill Biopharma LTD located?
Redhill Biopharma LTD's physical address in SAM.gov is HaArba'a St 21, Tel Aviv-Yafo, Israel.
Is Redhill Biopharma LTD registered in SAM.gov?
Yes. Redhill Biopharma LTD's SAM.gov registration is active through December 1, 2026.
What is Redhill Biopharma LTD's most recent federal award?
Redhill Biopharma LTD's most recent federal contract award is Redhill biopharma LTD-opaganib as host-directed therapeutic for ebola virus disease (75A50124C00059), from Office of the Assistant Secretary for Preparedness and Response, on September 27, 2024.
On GovTribe
See Redhill Biopharma LTD's full federal record
- Federal contract awards
- IDV awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors